U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H16ClN3O
Molecular Weight 313.782
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMOXAPINE

SMILES

c1ccc2c(c1)N=C(c3cc(ccc3O2)Cl)N4CCNCC4

InChI

InChIKey=QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2

HIDE SMILES / InChI
Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMOXAPINE

Approved Use

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Launch Date

714873600000
Primary
AMOXAPINE

Approved Use

Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation.

Launch Date

714873600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.55 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
319 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.02 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXAPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Other AEs: Ataxia, Drowsiness...
Other AEs:
Ataxia (>1)
Drowsiness (14%)
Dry mouth (14%)
Constipation (12%)
Blurred vision (7%)
Anxiety (>1)
Insomnia (>1)
Nervousness (>1)
Nightmare (>1)
Restlessness (>1)
Palpitations (>1)
Tremor (>1)
Confusion (>1)
Excitement (>1)
Edema (>1)
Skin rash (>1)
Prolactin increased (>1)
Nausea (>1)
Dizziness (>1)
Headache (>1)
Fatigue (>1)
Weakness (>1)
Appetite excessive (>1)
Perspiration excessive (>1)
Accommodation disturbance (<1%)
Mydriasis (<1%)
Micturition disorder (<1%)
Urinary retention (<1%)
Nasal stuffiness (<1%)
Hypotension (<1%)
Hypertension (<1%)
Syncope (<1%)
Tachycardia (<1%)
Drug fever (<1%)
Urticaria (<1%)
Photosensitized (<1%)
Pruritus (<1%)
Vasculitis (<1%)
Hepatitis (<1%)
Tingling (<1%)
Tinnitus (<1%)
Disorientation (<1%)
Seizures (<1%)
Hypomania (<1%)
Numbness (<1%)
Incoordination (<1%)
Concentration impairment (<1%)
Hyperthermia (<1%)
Extrapyramidal symptoms (<1%)
Tardive dyskinesia (<1%)
Leukopenia (<1%)
Agranulocytosis (<1%)
Epigastric distress (<1%)
Vomiting (<1%)
Flatulence (<1%)
Abdominal pain (<1%)
Taste peculiar (<1%)
Diarrhea (<1%)
Impotence (<1%)
Menstrual irregularity (<1%)
Breast enlargement (<1%)
Inappropriate antidiuretic hormone secretion (<1%)
Galactorrhea (<1%)
Lacrimation (<1%)
Weight gain (<1%)
Weight loss (<1%)
Impaired liver function (<1%)
Painful ejaculation (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Constipation 12%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Drowsiness 14%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Dry mouth 14%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Blurred vision 7%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Abdominal pain <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Accommodation disturbance <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Agranulocytosis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Breast enlargement <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Concentration impairment <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Diarrhea <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Disorientation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Drug fever <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Epigastric distress <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Extrapyramidal symptoms <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Flatulence <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Galactorrhea <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Hepatitis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Hypertension <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Hyperthermia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Hypomania <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Hypotension <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Impaired liver function <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Impotence <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Inappropriate antidiuretic hormone secretion <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Incoordination <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Lacrimation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Leukopenia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Menstrual irregularity <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Micturition disorder <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Mydriasis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Nasal stuffiness <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Numbness <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Painful ejaculation <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Photosensitized <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Pruritus <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Seizures <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Syncope <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Tachycardia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Tardive dyskinesia <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Taste peculiar <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Tingling <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Tinnitus <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Urinary retention <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Urticaria <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Vasculitis <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Vomiting <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Weight gain <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Weight loss <1%
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Anxiety >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Appetite excessive >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Ataxia >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Confusion >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Dizziness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Edema >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Excitement >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Fatigue >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Headache >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Insomnia >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Nausea >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Nervousness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Nightmare >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Palpitations >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Perspiration excessive >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Prolactin increased >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Restlessness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Skin rash >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Tremor >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Weakness >1
300 mg 1 times / day steady, oral
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Amoxapine-associated acute renal failure.
1985 Jun
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats.
1985 Oct
Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine.
1985 Oct
Amoxapine-induced extrapyramidal effects.
1986 Jun
Amoxapine-induced cognitive impairment in two patients.
1987 Apr
Acute myocardial failure following amoxapine intoxication.
1988 Feb
Biochemical evidence that high concentrations of the antidepressant amoxapine may cause inhibition of mitochondrial electron transport.
1988 Mar 30
A possible mechanism of toxicity by the antidepressant amoxapine based on its effects in three in vitro models.
1989
The clinical pharmacology of depressive states.
2002 Mar
The role of substance P in depression: therapeutic implications.
2002 Mar
[Case of amoxapine-induced refractory status epilepticus which was successfully treated with propofol].
2006 Oct
Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: case reports and review of the literature.
2007 Dec
Amoxapine as an antipsychotic: comparative study versus haloperidol.
2007 Dec
Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
2007 Jul 26
A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs.
2007 Mar
Differential distribution of glycine transporters in Müller cells and neurons in amphibian retinas.
2007 Mar-Apr
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.
2007 May
Pharmacological causes of hyperprolactinemia.
2007 Oct
Prevalence and predictors of antidepressant use in a cohort of pregnant women.
2007 Sep
Effects of different antidepressant treatments on the core of depression.
2008
An autopsy case of poisoning with ethanol and psychotropic drugs.
2008 Apr
Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.
2008 Dec
Amoxapine-associated acute respiratory distress.
2008 Jan
Determination of tricyclic antidepressants in human plasma using pipette tip solid-phase extraction and gas chromatography-mass spectrometry.
2008 Jul
Functional expression of the glycine transporter 1 on bullfrog retinal cones.
2008 Nov 19
Effectiveness of a multifactorial cardiovascular risk reduction clinic for diabetes patients with depression.
2008 Oct
Depression following thrombotic cardiovascular events in elderly medicare beneficiaries: risk of morbidity and mortality.
2009
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009 Dec 2
5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials.
2009 Jun
Persistence and compliance to antidepressant treatment in patients with depression: a chart review.
2009 Jun 16
Accuracy of Veterans Affairs databases for diagnoses of chronic diseases.
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Amoxapine-induced tardive dyskinesia.
2009 Oct-Dec
A new strategy for antidepressant prescription.
2010
Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report.
2010 Apr
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma.
2010 Dec
Determination of amoxapine and nortriptyline in blood plasma and serum by salt-assisted liquid-liquid microextraction and high-performance liquid chromatography.
2010 Dec
Evaluation and performance of desorption electrospray ionization using a triple quadrupole mass spectrometer for quantitation of pharmaceuticals in plasma.
2010 Feb
Amoxapine inhibits the delayed rectifier outward K+ current in mouse cortical neurons via cAMP/protein kinase A pathways.
2010 Feb
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes.
2010 Jan
Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect.
2010 Jan
Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database.
2010 Mar
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
2010 May
Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data.
2010 May 17
Gene expression profile analysis of genes in rat hippocampus from antidepressant treated rats using DNA microarray.
2010 Nov 30
Tricyclic antidepressants and headaches: systematic review and meta-analysis.
2010 Oct 20
Refractory hypotension during general anaesthesia caused by the long-term use of amoxapine.
2010 Sep
Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.
2011
Patents

Sample Use Guides

Usual effective dosage is 200 to 300 mg daily. Three weeks constitutes an adequate period of trial providing dosage has reached 300 mg daily (or lower level of tolerance) for at least two weeks. If no response is seen at 300 mg, dosage may be increased, depending upon tolerance, up to 400 mg daily.
Route of Administration: Oral
Cells (mouse cortical neurons) were incubated with or without amoxapine varying concentrations of 10, 50, and 100 uM. At a concentration of 10 to 500 uM, amoxapine reversibly inhibited I(K) in a dose-dependent manner and modulated both steady-state activation and inactivation properties.
Name Type Language
AMOXAPINE
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
AMOXAPINE [USP MONOGRAPH]
Common Name English
AMOXAPINE [VANDF]
Common Name English
2-CHLORO-11-(1-PIPERAZINYL)DIBENZ(B,F)(1,4)OXAZEPINE
Systematic Name English
NSC-759559
Code English
CL-67,772
Code English
DIBENZ(B,F)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-
Systematic Name English
AMOXAPINE [INN]
Common Name English
AMOXAPINE [USP-RS]
Common Name English
CL 67772
Code English
AMOXAPINE [USP]
Common Name English
CL 67,772
Code English
LOXAPINE SUCCINATE IMPURITY, AMOXAPINE- [USP]
Common Name English
AMOXAPINE [MI]
Common Name English
AMOXAPINE [JAN]
Common Name English
AMOXAPINE [ORANGE BOOK]
Common Name English
ASENDIN
Brand Name English
AMOXAPINE [MART.]
Common Name English
AMOXAPINE [USAN]
Common Name English
CL-67772
Code English
Classification Tree Code System Code
WHO-VATC QN06AA17
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
NDF-RT N0000175752
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
WHO-ATC N06AA17
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
LIVERTOX 48
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
NCI_THESAURUS C94727
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
Code System Code Type Description
DRUG CENTRAL
191
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
EVMPD
SUB05479MIG
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
LACTMED
Amoxapine
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
RXCUI
722
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY RxNorm
FDA UNII
R63VQ857OT
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
CAS
14028-44-5
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
IUPHAR
201
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
MERCK INDEX
M1843
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
237-867-1
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
INN
3049
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
DRUG BANK
DB00543
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
USP_CATALOG
1031401
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY USP-RS
EPA CompTox
14028-44-5
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
WIKIPEDIA
Amoxapine
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
PUBCHEM
2170
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
MESH
D000657
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
ChEMBL
CHEMBL1113
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY
NCI_THESAURUS
C47397
Created by admin on Fri Jun 25 21:01:25 UTC 2021 , Edited by admin on Fri Jun 25 21:01:25 UTC 2021
PRIMARY